Low-dose methotrexate in rheumatoid arthritis: a potential risk factor for bisphosphonate-induced osteonecrosis of the jaw
We present three patients with osteoporosis and rheumatoid arthritis [RA] who consumed oral bisphosphonates [alendronate] for less than 1 year and developed BIONJ within 2 to 5 months of undergoing a traumatic dental procedure. The patients also gave a history of consuming low doses of methotrex ate [disease-modifying anti-rheumatic drugs] up to 20 mg weekly for 4 to 10 years. No history of steroid consumption was given by any of the patients. This case series highlights the possibility of rheumatoid arthritis and low-dose methotrexate being potential risk factors for BIONJ. This may be o n account of the synergistic effect of methotrexate and bisphosphonates and the pro-inflammatory state created by RA which increased the risk of acquiring BIONJ.
Source: Oral and Maxillofacial Surgery - Category: ENT & OMF Source Type: research
More News: Anemia | Arthritis | Chemotherapy | Corticosteroid Therapy | Diabetes | Endocrinology | ENT & OMF | Methotrexate | Orthopaedics | Osteoporosis | Rheumatoid Arthritis | Rheumatology